MedTrace Logo

Phase I Study of TENPA in Advanced Solid Cancer

NCT02979392 · Status: TERMINATED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 19

Last updated 2019-09-25

No results posted yet for this study

Summary

The purpose of this study is to investigate the safety and to determine maximum tolerated dose and recommended phase 2 dose of TENPA (Targeting-Enhancing Nanoparticles of Paclitaxel) in patients with advanced solid tumor.

Conditions

  • Advanced Solid Tumor

Interventions

DRUG

TENPA (Targeting-Enhancing Nanoparticles of Paclitaxel)

TENPA IV once every 3 weeks (Phase I starting dose 75 mg/m2)

Sponsors & Collaborators

  • Yung-Jue Bang

    lead OTHER

Principal Investigators

  • Yung-Jue Bang · Seoul National University Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
20 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-05-02
Primary Completion
2019-07-04
Completion
2019-07-04

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02979392 on ClinicalTrials.gov